The low membrane permeability of candidate drug molecules is a major challenge in drug development and insufficient permeability is one reason for the failure of antibiotic treatment against bacteria.
giant unilamellar vesicles (GUVs), offer the advantages of having well-defined lipid compositions, being easy to image and also being more controlled systems for studying transport processes than a living bacterium. Due to these advantages, liposomes have been the subject of intensive research and their applications now reach far beyond the drug delivery 10 and synthetic biology communities [11] [12] [13] .
Various methods to produce lipid vesicles have been developed 14 . Albeit offering good control over lipid composition, many technologies such as electroformation suffer from drawbacks such as low yield, batch-to-batch variability, low encapsulation efficiency and polydispersity; these problems are especially acute at high salt concentrations and when using charged lipids 15 . Microfluidic methods to form liposomes can overcome these limitations, but often require oil as the lipid carrying solvent, which must be removed in further procedures 16 . The recently developed microfluidic technique octanolassisted liposome assembly (OLA) replaces the oil phase with the aliphatic alcohol 1-octanol 17 . A double emulsion of water in octanol self-assembles into a liposome with an octanol pocket attached to it upon production. The octanol pocket later pinches off within a few minutes, resulting in a liposome and a separated octanol droplet.
We have previously presented an optofluidic permeability assay which allows us to determine the permeability coefficient of electroformed GUVs to fluoroquinolone drugs in a direct, label-free manner 18 .
The assay exploits the autofluorescence property of fluoroquinolones in the ultraviolet for label-free detection. GUVs are exposed to a drug solute in a controlled manner in a microfluidic device. We use ultraviolet video fluorescence microscopy to quantify drug uptake in the GUVs and report the permeability coefficient of the drug across the membrane composition of interest. We used this method to show the influence of lipid composition on fluoroquinolone transport 19 . Furthermore, we showed that the permeability of different drugs from the fluoroquinolone family can span over two orders of magnitude at different pH levels 20 . Finally, we used the assay to study the transport behaviour of proteoliposomes containing the E. coli outer membrane protein OmpF 21 , thus developing a direct, optical measurement for antibiotic flux through porins, which form an important route for drug molecules to translocate across the outer membrane of Gram-negative bacteria 5 .
Despite these advances, the technique suffered from the various drawbacks of off-chip liposome formation described above. In this paper, we present the successful integration of the OLA platform with our optofluidic transport assay. This lab-on-chip total analysis platform enables the continuous production and screening of liposomes on the same device. This enabled us to efficiently screen an order of magnitude more liposomes than in our earlier platform. Importantly, it also enables us to explore transport using physiological salt concentrations which was challenging using electroformed GUVs 22 .
We also present an improved MATLAB analysis routine, which offers superior liposome detection, automatic channel recognition and more debugging options than our earlier platform. The method was validated by performing transport experiments of the fluoroquinolone norfloxacin through biomimetic PGPC liposomal membranes. We verified that the liposomes produced are indeed unilamellar by performing a dithionite bleaching assay.
II.

Experimental Design
Microfluidic Chip Design
The microfluidic device integrates the channel features used for octanol-assisted liposome assembly (OLA) with a downstream T-junction geometry to form a complete lab-on-chip system for the continuous production and screening of liposomes. A schematic of the device is shown in Fig 1A. 
Figure 1. Microfluidic total analysis system for quantifying drug permeability across liposome membranes. A: The microfluidic chip features four inlets, one outlet and two different channel heights.
The outer aqueous, inner aqueous and lipid-octanol inlets are needed for liposome production on chip.
The fourth inlet is used to flush in the drug whose permeability is to be measured. The liposome production occurs at a 6-way junction, where the aqueous flows meet the lipid-octanol phase (I). The 1-octanol pocket which is initially attached to the liposome separates from it in the post-junction channel within minutes after production (II). After an increase in channel height (III), the liposomes are mixed with the drug solute (IV). The transport measurement takes place as the liposomes flow towards the outlet, immersed in a bath of the autofluorescing drug (V). B: Mechanism to separate the liposome population from the octanol droplets. The liposomes typically have radii of 15-18 µm upon production and octanol droplets of < 8 µm. The channel height post formation is lower than the diameter of the liposomes which leads to a significant difference in velocity for octanol droplets and liposomes as indicated by the arrows. The octanol droplets pass through the device first and are discarded at the outlet. C: Upon production, the liposomes' diameters are larger than the height of the microfluidic channel. An increase in channel height from 16 µm to 35 µm frees the liposomes from the geometric confinement and enables transport measurements across the membrane without the risk of shearinduced leakage.
The 6-way junction where the liposomes are created is shown in Fig. 2A . The original design geometry 17 was modified to fit the needs of the drug transport assay. The dimensions of the junction were scaled up by a factor of 2 to achieve liposome diameters of up to 35 µm. The larger channels furthermore lead to higher flow rates and higher liposome production rates. A side effect of the larger liposomes is that the budding off of the octanol pocket from the liposomes requires more time than for smaller vesicles.
The budding off process has previously been reported to occur within a minute after production 23 , whereas this process is on the time scale of minutes using our chip geometry. The general mechanism of double-emulsion formation and separation into a liposome and a 1-octanol droplet remains the same as previously reported 17 . The generated liposomes have diameters larger than the height of the post-junction channel. These liposomes therefore initially shear along the PDMS walls, as they flow downstream. To ensure that the shear does not compromise the membranes during the subsequent transport measurements, an increment in channel height was introduced, increasing the channel height from 16 µm to 35 µm ( Fig. 1C ). Post the step, the liposomes flow towards the mixing junction without shearing.
Reaching the T-junction, the liposomes are exposed to a drug solute as they flow towards the outlet channel ( Fig. 2B ). Drug transport across the liposome membrane is tracked label-free by exploiting the autofluorescence of the drug in the UV region (λex = 350 nm). The liposomes initially appear dark on a bright background due to the lack of fluorescent drug molecules within them. As the fluorescent drug molecules diffuse through the membrane, the liposomes get brighter, as seen in Fig. 2C . We record and analyse the increase in fluorescence intensity using a previously established analytical protocol to quantify the permeability coefficient of the drug molecule for the specific lipid composition under investigation 18, 20 .
Separation of Octanol Droplets and Liposomes Based on Flow Speed
The shearing of the liposomes in the post-junction channel is exploited to separate the liposome population from the octanol droplets. This separation mechanism, visualized in Fig. 1B , is based on the difference in flow speeds between the liposomes and the droplets. Upon production, the liposomes typically have radii of 15-18 µm, whereas the octanol droplets have radii of under 8 µm. The channel height of 16 µm before the step causes deformation and shearing of the liposomes with the PDMS and slows their flow speed down considerably. In comparison, the smaller octanol droplets do not shear and therefore possess a higher velocity. Liposomes typically move with speeds of ~0.05 mm/s, whereas the droplets move at ~0.2 mm/s in this region of the chip. By stopping the lipid-octanol flow after a desirable number of liposomes is created and filling the post junction channel, this mechanism leads to a separation of the two populations. The octanol droplets get flushed through, while the GUVs remain in the chip. After reaching the step, the liposomes are no longer pressed against the channel wall, reconfigure to an expected isotropic spherical geometry and encounter the drug flow at the T-junction.
III. Materials and Methods
Chip Fabrication
The microfluidic chips are made of polydimethylsiloxane (PDMS) using established photo-and softlithography techniques. The master mold is generated by spin coating a thin layer of SU-8 2025 photoresist (Chestech, UK) on a 4-inch Silicon wafer (University Wafer, USA). The wafer is pre-baked on a hot plate at 65°C for 1 min and at 95°C for 6 min. The structures are imprinted on the substrate using a table-top laser direct imaging (LDI) system (LPKF ProtoLaser LDI, Germany). The LDI system exposes the structures specified in the software directly with UV light, causing the photoresist to crosslink and solidify. After exposure, the wafer is post-baked for 1 min at 65°C and for 6 min at 95°C.
The substrate is developed by rinsing the wafer with propylene glycol monomethyl ether acetate (PGMEA), which removes the unexposed photoresist and leaves the desired UV-exposed structures on the substrate. The wafer is then hard baked for 15 min at 120°C. The multi-height feature is achieved by performing this photo-lithography process twice on the same silicon wafer with different layers of photoresist with varying heights. Feature heights of 16 µm and 35 µm respectively were obtained by spinning the photoresist at 3800 rpm and 1800 rpm respectively (WS-650-23NPP, Laurell Technologies, USA) for 60 s with a ramp of 100 rpm/s. The anchoring tool of the direct laser writer is used for aligning the features in the two designs.
The PDMS microfluidic devices are made by using the silicon master as a mold. Liquid PDMS (Sylgard 184, Dow Corning) is mixed in a 9:1 ratio with the curing agent and desiccated to remove air bubbles.
It is then cast into the mold and cured for 60 min at 60°C. Fluid access ports of 0.75 mm diameter for the inlets and 1.5 mm diameter for the outlet are punched into the chip using biopsy punches (WPI, UK). The PDMS chip is then plasma-bonded to PDMS-coated cover slips using a standard plasma bonding protocol (100 W, 10 s exposure, 25 sccm, plasma oven from Diener Electric, Germany).
The surfaces of the outlet channel are rendered hydrophilic by flushing the channel with a polyvinyl alcohol (PVA) solution for 15 min (50 mg/mL, 87-90% hydrolysed molecular weight 30,000-70,000 Da, Sigma-Aldrich) via the outer aqueous inlet, using a previously established protocol 17 . Post treatment, the PVA is removed from the channels by applying suction with a vacuum pump (Gardner Denver Thomas GmbH, Germany) after which the microfluidic device is baked in the oven at 120°C for 15 min.
Optical Setup
A 
Solution Compositions and Flow Control
The base solutions for the OLA aqueous phases consist of 200 mM sucrose and 15% v/v glycerol in buffer. In accordance to previously published protocols, the outer aqueous phase additionally contains 50 mg/mL poloxamer Kolliphor P-188, which facilitates the initial double-emulsion formation 23 .
Experiments are performed in two different chemical environments. Transport is measured in 
Experimental Protocol
The microfluidic assay involves a 2-stage protocol. The first stage involves adjusting the pressure-driven flows of the liquids to obtain stable liposome production, as reported previously 17 The next stage involves the drug permeability measurement, using the same measurement principles previously employed in our laboratory [18] [19] [20] [21] . The field-of-view is changed to the channel network post the T-junction, shortly after the liposomes encounter the drug flow (Fig. 2C ). Using a 60× water immersion objective (UPLSAPO, NA 1.2, Olympus), two sections of the channel are monitored simultaneously with sufficient resolution to study the transport process. Since the liposome is dispensed in the drug solution flowing along the channel, the different positions in the channel correspond to different drug exposure times of the liposome. The IA and OA pressures are maintained at 15 mbar each, resulting in flow speeds in the channel of about 0.5 mm/s. One measurement is taken just after the drug and the vesicle flows meet (t ≈ 0 s), the other one typically after the liposomes have been exposed to the drug for ~15 seconds. Measurements of up to 40 seconds of drug exposure can be obtained at these flow rates by recording the liposomes at the end of the channel network, just before the outlet reservoir. This can be further increased by increasing the length of the mixing channel 18 .
After all the liposomes have been flushed through, the liposome formation can be restarted, and the experiment repeated. The number of repeats is limited by the quality of the PVA coating and/or accumulation of lipid and octanol aggregates in the chip. We achieved up to four such repeats on a single microfluidic device.
Data Processing and Permeability Calculation
The data is analysed using our previously established permeability model 18, 20, 21 . The videos obtained are processed using the MATLAB script provided in the Supplementary Materials. Similar to our previously reported analysis routine, the script extracts the radius, the speed, the circularity and the intensity values of the liposomes passing through the channels. We have updated the image analysis routine, which now additionally features superior liposome detection, automatic channel recognition and debugging options that are explained in detail in the Supplementary Information.
The permeability coefficient is obtained by the equation 18 :
Where the variable R is the radius of the liposome, t is the time of its exposure to the antibiotic and ΔI is the normalized autofluorescence intensity difference between the interior ( ) and the exterior ( ) of the liposome:
The difference in the normalized intensity of the liposomes at different drug exposure times can be used as a direct readout of drug flux into the liposomes 18 . Due to the initial lack of fluorescing drug molecules inside the liposome, ( = 0) has a high value, correlating to a large difference in fluorescence intensity between the liposome ( ) and the background ( ). In contrast, ∆ ( ) at the later time point has a lower value consistent to a lower difference in fluorescence intensity between the liposome and the background, due to the influx of fluorescing drug molecules. Further explanations and a derivation of Equation (1) have been published in our previous work 18, 20 .
IV. Test for Membrane Unilamellarity
Liposomes produced by OLA have previously been tested for their unilamellarity via the incorporation of the pore forming toxin -hemolysin 17 . Additionally, the antimicrobial peptide cecropin B was found to permeabilise and lyse OLA-produced liposomes, again suggesting that the liposomes are unilamellar 27 .
As an additional, quantitative technique to verify the unilamellarity of the OLA-produced liposomes, we extracted the liposomes from our microfluidic device and subjected them to a dithionite bleaching assay.
If brought in contact with it, the membrane-impermeable anion dithionite reduces and thereby irreversibly bleaches nitrobenzoxadiazole (NBD). By subjecting unilamellar liposomes containing NBDlabelled lipids to a dithionite solution, the fluorescence intensity of the liposome drops to half of the initial value, due to the bleaching of the outer leaflet of the bilayer membrane 28, 29 .
The composition of the inner and outer aqueous solutions used for liposome production in this experiment is identical to the solutions of the drug transport assay described above. The intensity traces of the liposomes normalized to their initial intensity value are depicted in Figure 3 . 
V. Results and Discussion
Passive Diffusion Measurement of Norfloxacin
Drug transport measurements were performed in two different chemical environments. One set of measurements was performed using physiological salt and pH conditions (PBS). The second set was taken as a control in an acetic acid buffer at pH 5. The majority of norfloxacin molecules are positively charged at pH 5 whereas the proportion of uncharged molecules is increased at pH 7.4 18, 20, 21, 30 . The liposomes consisted of PCPG lipids in a 3:1 ratio, a mixture which is commonly used as a model for bacterial membranes due to its negative charge 25, 26 . The scatter plots in Fig. 4 show representative results from such experiments. The black data points mark the normalized intensity difference levels (0) of individual liposomes at the first measurement point, when the liposomes have just encountered the drug flow and hence do not contain any drug molecules within them. The coloured data points mark the normalized intensity difference ∆ ( ) of the individual liposomes after they have been exposed to the drug for the time indicated inset. The liposomes in PBS show a substantial drop in ∆ after being exposed to the drug, whereas the measurements at the different time points overlap when the studies are conducted at pH 5.
Since the drop in ∆ is a direct result of the influx of fluorescent molecules, we can conclude that no significant transport occurs at pH 5 over the observed timespans, whereas there is substantial norfloxacin transport at physiological pH and salt conditions. The technical repeats of this experiment shown in Fig. S3 and Fig. S4 (ESI) report similar results. Expanding the exposure and observation time for the pH 5 measurement to 40 seconds yields the same result of no significant transport, in line with our previous observations. This also confirms that the liposome membranes are not being compromised due to shear or any other interactions in our device.
The observed transport behaviour is to be expected, as the norfloxacin molecule is predominantly uncharged or zwitterionic at neutral pH, whereas the molecule is in a charged state at pH 5 31 . Lipid membranes are generally regarded as largely impermeable to ions and highly charged molecules, since these cannot cross the hydrocarbon section of the lipid bilayer easily. In nature, these transport processes are governed by transmembrane proteins such as porins or ion channels 32 .
The spread in vesicle radius observed in Fig. 4 is a result of the method used to separate the liposomes from the octanol droplet population. As illustrated in Fig. 1B , the mechanism is based on a difference in flow velocity in the channel due to shearing of the liposomes. Throughout their travel to the step in channel height, the membranes are susceptible to small disruptions due to shear. The disruptions can lead to shrinking and separation of the liposomes. This spread in liposome size is illustrated in Fig. S2 (ESI) . The gradient of the curve that the scatter points lie on is a result of the fact that our optical measurement is not a confocal measurement. The fluorescent drug solute surrounding smaller liposomes therefore leads to a lower apparent ∆ , compared to larger liposomes (for a detailed explanation, please refer to Cama et al. 18 ). The analysis protocols are hence identical to our previously established technique. 
VI. Conclusion
In this paper, we presented an integrated microfluidic platform for quantifying drug permeation across biomimetic membranes. We combined an on-chip liposome formation technique (OLA) with a downstream T-junction for the controlled exposure of liposomes to a drug solute. Norfloxacin transport through biomimetic PGPC (1:3 ratio) liposomes was measured at physiological salt and pH conditions and yielded a permeability coefficient of 4.13 ± 0.05 x 10 -6 cm/s (mean ± std. error of mean) and a median value of 3.57 x 10 -6 cm/s, which is in good agreement with previous measurements 19 .
Since our method directly quantifies the permeability coefficient of the drug across the specific membrane of interest, our technique offers an alternative to traditional drug transport assays such as octanol-partition coefficients, or the parallel artificial membrane permeability assay (PAMPA) which suffer from multiple drawbacks 33, 34 . Our method also profits from recent advances in the development of fluorescent antibiotics, as these provide another potential tool for studying and understanding drug transport processes that will lead to further insight into drug-membrane interactions 35 . Importantly, thanks to the microfluidic character of our method, we require only very small reagent volumes in the microliter range for our measurements 36 .
Another advantage of the integrated on-chip technique presented here over our previously published optofluidic permeability assay lies in the benefits of controlling liposome formation with OLA. OLA allows the formation of large numbers of liposomes with physiological salt concentrations and with complex lipid mixtures. Other techniques such as electroformation suffer from very low yields in this environment 15 , or in the case of other microfluidic techniques, require extensive procedures to remove oil remnants associated with the production 17 . Moreover, OLA allows for the efficient encapsulation of desired solutes inside the vesicles upon production 17, 27 . This makes it an interesting technique for biosensor-based approaches to detect drug molecules 37 .
The microfluidic platform can be expanded to study more complex membrane compositions and proteins. The technique could therefore be used for the formation and study of proteoliposomes, potentially offering an alternative to current reconstitution techniques 38 . Membrane transporters are an interesting field of study on multiple levels. On one side, they play a crucial role in drug uptake in bacteria and mutations of membrane proteins have been associated with antibiotic resistance 21, 39 . On the other side, membrane transporters in the liver and kidney control the systemic clearance of drugs 40 . They therefore govern drug concentration profiles in the body with major effects on drug efficacy. Both these and other membrane transport-related questions can be addressed with our platform. 
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